ABUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Arbutus Biopharma's total current assets for the quarter that ended in Dec. 2023 was $132.03 Mil.
The historical data trend for Arbutus Biopharma's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Current Assets | Get a 7-Day Free Trial | 93.83 | 127.70 | 160.66 | 151.14 | 132.03 |
Arbutus Biopharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Current Assets | Get a 7-Day Free Trial | 151.14 | 152.85 | 158.80 | 141.61 | 132.03 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Arbutus Biopharma's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 126.003 | + | 1.776 | + | 0 | + | 4.248 | |
= | 132.03 |
Arbutus Biopharma's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 126.003 | + | 1.776 | + | 0 | + | 4.248 | |
= | 132.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Arbutus Biopharma (NAS:ABUS) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Arbutus Biopharma's Liquidation Value for the quarter that ended in Dec. 2023 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 126.003 | - | 38.383 | + | 0.75 * 1.776 | + | 0.5 * 0 |
= | 88.95 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Arbutus Biopharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Melissa Rewolinski | director | 9000 STATE ROAD, PHILADELPHIA PA 19136 |
Karen Sims | officer: Chief Medical Officer | 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
J. Christopher Naftzger | officer: General Counsel and CCO | 633 LOWTHER ROAD, LEWISBERRY PA 17339 |
Michael J. Sofia | officer: Chief Scientific Officer | C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Tram Tran | director | C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Michael J. Mcelhaugh | officer: Chief Business Officer | C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
James R Meyers | director | GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew Cheng | director | 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
William H. Collier | director, officer: President and CEO | C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974 |
Elizabeth Howard | officer: Executive VP & General Counsel | 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
David C Hastings | officer: Chief Financial Officer | C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Gaston Picchio | officer: Chief Development Officer | C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
From GuruFocus
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 04-25-2023
By PRNewswire PRNewswire • 04-26-2023
By Marketwired • 10-24-2023
By Marketwired • 09-11-2023
By Marketwired • 06-21-2023
By Marketwired • 06-21-2023
By sperokesalga sperokesalga • 06-21-2023
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 10-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.